Shuffle for fans

This Week in Virology


This Week in Virology is a netcast about viruses - the kind that make you sick.

Popular episodes

TWiV 835: Giving thanks for antibodies

Nov 28 • 01:39:01

TWiV reviews why children should be vaccinated against COVID-19, increased risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variant compared to Alpha variant in vaccinated but not recovered individuals, and immune correlates of protection from the mRNA-1273 vaccine efficacy trial....

TWiV 834: COVID-19 clinical update #90 with Dr. Daniel Griffin

Nov 27 • 41:10

In COVID-19 clinical update #90, Dr. Griffin covers FDA expansion for booster doses, 3 more at home antigen tests approved by FDA, immune correlates analysis of mRNA-1273 vaccine, risk for stillbirth, PROVENT prophylaxis trial results, fluvoxamine recommendations, advice on molnupiravir, automated text messaging service for monitoring illness, and long COVID-19 after vacci...

TWiV 833: Grand theft kinesin

Nov 25 • 01:32:25

TWiV reviews Michael Worobey’s dissection of the early COVID-19 cases in Wuhan, and the discovery that herpesviruses assimilate cellular kinesin to produce motorized virus particles....

TWiV 832: Heavy metal flu fighters

Nov 21 • 01:51:36

TWiV reviews the vials labeled smallpox that were not, re-emergence of enterovirus D68 in Europe, efficacy of inactivated SARS-CoV-2 vaccine, and cellular correlates of protection for an oral influenza virus vaccine....

TWiV 831: COVID-19 clinical update #89 with Dr. Daniel Griffin

Nov 20 • 41:04

In COVID-19 clinical update #89, Dr. Griffin reviews upcoming meeting on FDA emergency use authorization for molnupiravir, 25% of US cases in children, reinfection associates with presence of antibodies, national surveillance for acute flaccid myelitis in the US, and monoclonal antibody treatment of infection in vaccinated, high-risk individuals....

TWiV 830: A culture of resistance

Nov 18 • 02:08:13

TWiV explains that a recent report suggesting that the SARS-CoV-2 spike protein inhibits V(D)J recombination in vitro would not impact immunity after infection or vaccination, and describes the isolation of remdesivir resistant mutants in cells in culture, and the emergence of amino acid changes in the spike protein identical to those in variants of concern, in the absence...

TWiV 829: Antiviral and cytotoxically empowered for COVID-19

Nov 14 • 01:43:31

A TWiV duo reviews how SARS-CoV-2 attacks the olfactory mucosa but spares the olfactory bulb, vaccination with BNT162b2 induces virus-specific stem cell memory T cells, and development of an oral protease inhibitor for the treatment of COVID-19....

TWiV 828: COVID-19 clinical update #88 with Dr. Daniel Griffin

Nov 13 • 33:17

In COVID-19 clinical update #88, Dr. Griffin covers vaccine protection among US veterans, absence of long COVID in vaccinated who are infected, single dose of REGEN-COV monoclonal antibody cocktail provides long term protection, and Pfizer protease inhibitor Paxlovid is 89% effective in preventing hospitalization or death....

TWiV 827: A shot to save the world with Greg Zuckerman

Nov 7 • 01:51:39

Greg Zuckerman joins TWiV to discuss his book that explores the race to produce COVID-19 vaccines, with insights into the companies, scientists, and executives involved and the rivalries, ambitions, ego, and a desire to save the world....

TWiV 826: COVID-19 clinical update #87 with Dr. Daniel Griffin

Nov 6 • 48:50

In COVID-19 clinical update #87, Dr. Griffin reviews PCR cycle threshold and RNA copy number, rapid antigen tests, hospitalization rate after infection or vaccination, allergies and vaccination, community transmission and viral RNA load, early treatment with sotrovimab, meta-analysis of tocilizumab treatment, antibiotic overuse, and guidelines on the use of anticoagulation...

Check out similar podcasts

AstroVed's Astrology Podcast
Es así y punto con Hernán Pereyra
ESPN Deportes, Hernán Pereyra
Sports Criminals
Parcast Network
TwitterBlogCareersPress KitCommunity GuidelinesTerms of ServicePrivacy Policy
© 2021 Akora Labs, Inc.